Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Acebright Signs MOU for NasVax's Liver Disease Treatment

publication date: Sep 3, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Acebright Holdings of China announced new terms for its agreement with NasVax, an Israeli immunotherapy company. As before, Acebright will invest $1 million in NasVax. The company also signed a non-binding MOU that gives Acebright an exclusive right to develop NasVax's oral Anti-CD3 technology for fatty liver disease in Asia Pacific countries including China, India and others, but excluding Japan. More details....

Stock Symbol: (TASE: NSVX)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...